Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins
| Autor: | J. Girard, U Zumsteg, J L Rime, R P Zurbrügg, A Blumberg, Faruk Hadziselimovic |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Male
Infertility endocrine system medicine.medical_specialty Urinary system Radioimmunoassay Puberty Precocious Buserelin Follicle Internal medicine Testis medicine Humans Precocious puberty Child Administration Intranasal Bone Development Testicular atrophy business.industry Infant Bone age medicine.disease Endocrinology Child Preschool Gonadotropins Pituitary Pediatrics Perinatology and Child Health Female Atrophy business Luteinizing hormone Hormone |
| Zdroj: | European Journal of Pediatrics. 147:263-269 |
| ISSN: | 1432-1076 0340-6199 |
| Popis: | Daily subcutaneous doses of luteinizing hormonereleasing hormone (LHRH) analogues are a well-established therapy for gonadotropin-dependent precocious puberty. Reports on intranasally administered analogues, however, are controversial. We studied the effect of intranasal d-Ser (TBU)6-LHRH (BUS) on growth rate, skeletal maturation, and urinary gonadotropins in five girls and one boy with central precocious puberty (CPP) who had been treated for 1.4–2.3 years (mean 1.9). Because of the potential antifertility effects of LHRH analogues, testicular histology was analysed in the boy. In the five children with accelerated growth, the bone age-related velocity of heigh gain decreased from 10.58 ±2.77 to 5.82±1.8 cm/year (means±SD, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink